CYTOKINETICS INC — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cytokinetics announced positive Phase 3 ACACIA-HCM results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting both primary endpoints: KCCQ-CSS improvement of 3.0 points vs. placebo (p=0.021) and pVO2 improvement of 0.67 ml/kg/min vs. placebo (p=0.003) at 36 weeks. The company plans to submit a supplemental New Drug Application to the FDA in Q4 2026. The trial randomized 517 patients 1:1 with aficamten or placebo; aficamten showed consistent benefits across subgroups but also elevated serious adverse events (20.2% vs. 14.7% placebo) and LVEF decline ≥50% in 10.5% of treated patients.
Why this rating
First positive Phase 3 in nHCM expands addressable market (~$500M+ opportunity); materiality moderate due to safety signals, narrow primary endpoint margins, and regulatory uncertainty at $2.5B market cap.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $74.10 ▲ 0.15% | at our read · backfill $73.99 | +10 min · backfill $73.75 ▼ 0.33% | +30 min · backfill $73.11 ▼ 1.19% | +1 hr · backfill $74.00 ▲ 0.01% | +4 hrs · backfill $72.73 ▼ 1.70% |
The stock had already moved -0.15% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.